HOPE FOR A CURE....
BEGINS WITH RESEARCH

The research program was developed in 1995 to explore additional treatment options for patients of the practice. In March 2015, we joined the National Community Oncology Research Program (NCORP), essentially establishing a small satellite of the National Cancer Institute (NCI) in Arroyo Grande. This increases access to new NCI-sponsored clinical trials for local patients. Because of efficiencies in the NCORP, overhead for the research program decreased, permitting us to use more of our resources for research and patient services.

In addition to the trials listed we have access to about 75 clinical trials reviewed by the NCI CIRB.  If you are interested in a clinical trial that is not listed ask Ruth Mares (Ruth@PCROncology.com) if we have access to it.

 

Open Clinical Trials as of february 2021

 

CANCER MOONSHOT BIOREPOSITORY: As of February 28, 2021 PCR Oncology is the first and only location in California the NCI has invited to participate in the Cancer Moonshot Biorepository study.  The diseases under study are 

  • lung cancer,

  • colorectal cancer,

  • castrate-resistant prostate cancer,

  • melanoma and

  • multiple myeloma.

The basic eligibility criteria is that the patient must be on a first-line treatment for an incurable stage of one of these diseases.  Eligible patients who consent will have tissue submitted to the NCI for sequencing.  The NCI will send results of sequencing to patients and physicians with interpretation of sequencing data that includes comments about treatments likely to be effective and other treatments to which the cancer is likely resistant.  PCR Oncology will submit clinical data on outcomes of treatments to the NCI, allowing them to link clinical and genetic data.  Ultimately this should lead to an improved ability to pick treatments likely to benefit patients and avoid treatments to which cancers are resistant.  

Additional tumor specimens will be sought at time of progression of cancer and, when available, submitted to the NCI in order to determine the molecular/genetic basis of resistance, and to help select second-line treatments.

LEUKEMIA / LYMPHOMA / MYELOMA / MYELODYSPLASTIC

  • S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) patients with molecular evidence of disease.

BREAST CANCER

  • S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer.

BASKET TRIALS

  • EAY 131: Molecular Analysis for Therapy Choice (MATCH)

  • ULI-EAP-100: Expanded access to ulixertinib (BVD-523) in patients with advanced MAPK pathway-altered malignancies

LUNG

  • ECOG 4512-A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

  • LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

  • S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus standard of care in participants with Stage IV or Recurrent non-small cell lung cancer previously treated with Anti-PD-1 or Anti-PDL1 Therapy (Lung-Map Non-Match Sub-Study)

  • A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Gastro-Intestinal

Genito-Urinary

  • A031704: PD-inhibitor (Nivolumab)and Ipilimumab followed by nivolumab with or without VEGF TKI cabozantinib in metastatic untreated Renal Cell Cancer

 

For more information please contact:
Ruth Mares at Ruth@pcroncology.com or call (805) 474-9143